Press Releases

Sygnature Discovery successfully identifies potent SHP2 degrader compounds in collaboration with UBE Corporation

Creative Biostructure Announces New Method for Producing CRAL-TRIO Domain-Containing Proteins Using Virus-Like Particles

Creative Enzymes Launches Diamine Oxidase (Food-Grade) for Enhanced Food Safety and Digestive Health

CD Genomics Redefines RNA Sequencing with Revolutionary Ultra Low RNA Sequencing Technology

Creative Enzymes Unveils Custom Blends Product Line for Bioprocessing Solutions

CD Genomics Unveils Cutting-Edge DNA 6mA Sequencing Service for Epigenomic Research

Macleaya cordata Extract and Analysis Service Now Available at Lifeasible

Matexcel Launches New Line of Natural Extract Peptide Products for Research Use

Expanding Research Frontiers: CD Formulation Enables In Vitro Cytotoxicity Testing for Microspheres and Microneedles

Alfa Chemistry: Transforming Research Possibilities through Instrumental Analytical Reagents

NICE RECOMMENDS LILLY’S MIRIKIZUMAB (OMVOH ®▼) FOR THE TREATMENT OF ELIGIBLE ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Mirikizumab is the first IL-23p19 targeted biologic recommended by NICE for use within NHS England and Wales for treating moderately to severely active ulcerative colitis in adults.1,2. In two randomised, double-blind, placebo-controlled phase 3 trials, LUCENT-1 and LUCENT-2, mirikizumab achieved primary and key secondary endpoints, including sustained clinical remission. Decreases in bowel urgency severity were observed as early as week 2 in patients treated with mirikizumab versus placebo in LUCENT-1.2 Mirikizumab has been recommended through the NICE cost-comparison process meaning NHS England and commissioning groups have agreed to provide funding to implement this guidance within 30 days from publication of the technology appraisal guidance (TAG) rather than the standard 90 days, providing faster access to a new treatment option for eligible adults living with moderately to severely active ulcerative colitis1

Emmes Appoints Peter Ronco as Chief Executive Officer

Bora merges with Sunway Biotech to launch global Nutraceuticals offering

Nostics Appoints Medtech Leader Jeroen Nieuwenhuis as CEO

Nostics, a medical diagnostics startup, is thrilled to announce the appointment of veteran medtech entrepreneur, Jeroen Nieuwenhuis, as its new Chief Executive Officer. As the company prepares to introduce its revolutionary diagnostics technology to the point-of-care market, Jeroen's inclusion marks an important milestone in Nostics’ journey.

Mural Health Raises $8M Led by Bessemer Venture Partners to Accelerate Growth

Mural Health Raises $8M Led by Bessemer Venture Partners to Accelerate Growth Funding enables Mural Health to expand its Mural Link platform to modernize the clinical trial participant experience

Experts from CD Formulation Share Insights on How to Prepare Nano-vesicles for Encapsulating Protein Drugs

Biofourmis Accelerates and Simplifies Drug Development with Expanded Digital Clinical Trials Solution

Biofourmis Accelerates and Simplifies Drug Development with Expanded Digital Clinical Trials Solution

BioIVT Webinar Will Discuss How to Manage Uncooperative Drugs in In Vitro Transporter Research

This webinar will present practical strategies to achieve definitive results when researching unstable, sticky, or insoluble compounds.

Alfa Chemistry Unveils Revitalized Strong/Weak Acid Cation Resin and Base Anion Resin Lineup

uMed Partners with The Michael J. Fox Foundation to Support Wide-scale Study Exploring Link Between Smell Loss and Parkinson’s

Health and research tech company uMed is partnering with the Michael J. Fox foundation to run a smell test study to investigate the link between loss of smell and Parkinson’s disease. uMed’s technology and consumer-based marketing techniques will help the Michael J. Fox Foundation overcome traditional barriers to engaging clinical trial volunteers and reach a large, diverse patient cohort to accelerate the pace of research and access to potential breakthroughs.